ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Treatment of Obsessive-Compulsive Disorder (OCD) in Children

This study has been completed.

Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)

Purpose

The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs medication plus therapy. Some patients will receive an inactive placebo (PBO) instead of medication and/or Educational Support (ES, non-psychological treatment) instead of therapy.

One in 200 children suffer from OCD, but few receive appropriate treatment. Both CBT and medication seem to be effective, but their effectiveness, alone and in combination, has not been evaluated.

There are 2 phases to this trial. In Phase I the child will receive 1 of the following 6 treatments for 12 weeks: 1) SER alone; 2) pill PBO alone; 3) CBT alone; 4) SER plus CBT; 5) SER plus ES; 6) pill PBO plus ES. If the child responds to treatment, he/she will go on to Phase II in which the treatment will be slowly reduced, then stopped (discontinued), over time to test the treatment's durability. The child will be evaluated at Weeks 1, 4, 8, 12 (Phase I treatment), and Weeks 16, 20, 24, and 28 (Phase II discontinuation) to see how effective and durable the treatment is in treating your child's OCD.

A child may be eligible for this study if he/she: Has obsessive-compulsive disorder (OCD) and is 8 - 16 years old.

Condition Treatment or Intervention Phase
Obsessive-Compulsive Disorder
 Behavior: Cognitive Behavior Therapy
 Behavior: Educational Support
 Drug: Sertraline
Phase III

MedlinePlus related topics:  Obsessive-Compulsive Disorder

Study Type: Interventional
Study Design: Treatment, Placebo Control

Official Title: Treatment of Pediatric Obsessive-Compulsive Disorder

Further Study Details: 

Study start: May 1997;  Study completion: April 2002

To contrast the degree and durability of improvement in pediatric obsessive-compulsive disorder (OCD), patients will be treated with 1 of 6 conditions (3 active treatments and 3 control treatments): sertraline alone (SER), OCD-specific Cognitive Behavior Therapy (CBT), both SER and CBT (SER plus CBT), pill placebo (PBO), pill PBO plus Educational Support (ES), and SER plus ES.

One in 200 youth suffers from OCD, yet relatively few receive appropriate treatment. Both CBT and medication appear beneficial in controlled studies; however, the relative efficacy of CBT and medication, alone and in combination (COMB) is unknown. Thus, well-designed treatment outcome studies are necessary to improve care for youth with OCD.

The experimental design covers 2 phases. Phase I is a 2 (site) x 2 (SER or pill PBO) x 3 (CBT, ES or non- psychosocial treatment) x 5 (repeated measures) factorial 12-week comparison of SER, CBT, COMB and the control conditions. In Phase II, responders advance to a 16-week discontinuation study to assess treatment durability. The primary outcome measure is the Yale-Brown Obsessive-Compulsive Scale. Assessments blind to treatment status take place at Week 0 (pretreatment); Weeks 1, 4, 8, 12 (Phase I treatment); and Weeks 16, 20, 24 and 28 (Phase II discontinuation). Besides addressing comparative efficacy and durability of the specified treatments, the investigators also examine time-action effects, differential effects on specific aspects of OCD, including functional impairment, and predictors of response to treatment.

Eligibility

Ages Eligible for Study:  8 Years   -   16 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

Patients must have: DSM-IV diagnosed OCD.


Location Information


North Carolina
      Duke Univ. Med. Ctr., Durham,  North Carolina,  27710,  United States

Pennsylvania
      Univ of Pennsylvania, Philadelphia,  Pennsylvania,  19104,  United States

Study chairs or principal investigators

Edna B. Foa, PhD,  Principal Investigator
John S. March, MD, MPH,  Principal Investigator

More Information

Study ID Numbers:  MH55126; MH55121
Record last reviewed:  September 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00000384
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-10
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act